NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

Table 14 SVR dependence in null responders for various direct-acting antiviral combinations

Ref.	n	Combination	Duration	SVR
Zeuzem et al[39]	37	Telaprevir-based triple therapy	48 wk	33%
Bacon et al[25]	58	Boceprevir-based triple therapy	48 wk	52%
Lok et al[35]	11	DCV + ASV	24 wk	36%
Lok et al[35]	10	DCV + ASV + conventional therapy	24 wk	90%
Suzuki et al[36]	21
Poordad et al[37]	7	ABT-450 + ritonavir + АВТ-333 + ribavirin	12 wk	43%

DCV: Daclatasvir; ASV: Asunaprevir.